Crossject : Strategic update: no transformative announcements at this stage
>Update on the 2024 road map - Crossject provided an update yesterday on the group’s latest developments and its road map for 2024. The key takeaways were as follows: 1 / Progress of the regulatory process in the US for Zepizure: no change at this stage to the previously announced timetable. Despite ongoing discussions with the FDA, management still expects an Emergency Use Authorisation (EUA) in the coming weeks (we are modelling first shipments in Q2 2024). 2/ Comme...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.